New drug may free hypoparathyroidism patients from daily calcium pills
NCT ID NCT07299838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, palopegteriparatide, in 90 adults with chronic hypoparathyroidism. The goal was to see if the drug could help patients stop taking activated vitamin D and calcium supplements for at least four weeks. Researchers tracked how long it took to become supplement-free and monitored safety. The study was completed in Greece and provides real-world evidence on this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Laiko General Hospital
Athens, Attica, 11527, Greece